what is the difference between gip and glp 1 Two incretin hormones GLP-1 GIP: Comparison of their actions in insulin secretion and β cell preservation Targeting GLP-1, GIP & GCG

The brain is reward response to food intensifies

The number of type II diabetes patients accounted for about 95% of the total number of diabetes patients

And by 2023, poison centers logged more than 8,000 GLP-1-related calls.When researchers examined the increase by specific medication, semaglutide accounted for 64% of all GLP-1-related calls, according to the results.One researcher called its dominance "staggering," though she noted that the finding aligns with the drug's extensive media attention.Most of the cases resulted from unintentional dosing or therapeutic errors rather than deliberate misuse.Two of the most common mistakes were patients injecting semaglutide daily instead of weekly and patients starting at the full dose immediately rather than gradually increasing treatment as recommended.The majority of cases involved mild gastrointestinal symptoms

The risk was higher in three situations: Higher doses

Some key findings from the report include: More than 150 GLP-1 drug candidates, intended for the treatment of multiple indications, are currently either approved or being investigated by pharmaceutical companies

3.5 Skin side effects Injection site reactions, such as rash, erythema, or itching at the injection site, are common with GLP-1 receptor agonists ( Table 5 , in the Appendix)